Abstract submission is closed.



Date and time

  • Abstracts
  • Trial in Progress
  • Intent to submit LBA

4 February 2020
21:00 CEST (Central European Time)

Late-breaking abstracts

Final submission deadline* 1 April 2020
21:00 CEST (Central European Summer Time)

Late-breaking abstracts

*A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline (4 February 2020).

Final versions must be submitted by 1 April 2020, 12:00 CEST (Central European Summer Time).

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to Breast 2020.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 4 February 2020 will be considered for late-breaking status.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to Breast 2020.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design


  • Recruitment must have already begun or have been completed by the abstract submission deadline of 4 February 2020.
  • Abstracts including results or preliminary data will be rejected.
  • Authors of ‘encore’ TiP abstract submissions must supply information regarding the original presentation, indicating the name of the meeting and publication number. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
  • Trial in Progress abstracts will be accepted for Poster outcome only.

Outcome notifications

Outcome notifications are expected to be made available to first authors by March 2020.

Publication schedule of accepted abstracts

  1. Abstracts accepted for presentation during ESMO Breast Cancer 2020 (Proffered Paper, Mini Oral and Poster) and for publication in the ESMO Breast Cancer 2020 Abstract Book, will be published online on the ESMO Breast Cancer 2020 website on 4 May 2020.
  2. Late-breaking abstracts (LBA) accepted for presentation during ESMO Breast Cancer 2020 will be made public on the day of presentation during the official ESMO Breast Cancer 2020 Programme.
  3. Abstracts and LBAs selected for the official ESMO Breast Cancer 2020 Press Programme will be available 10 days before the Congress.


Date and time

Abstracts accepted as:

  • Proffered Paper (suffix ‘O’)
  • Mini Oral (suffix ‘O’)
  • Poster (suffix ‘P’)

4 May 2020 

12:00 Central European Summer Time (CEST)

Late-breaking abstracts (prefix ‘LBA’)

At the start of the official Congress session during which they are presented.

Abstracts and LBAs selected for the official ESMO Press Programme (additional suffix ‘PR’)

ESMO Press Programme and related abstract publication schedule, will be available 10 days before the Congress.

Presentation of accepted abstracts

The Breast 2020 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:

  • Proffered Paper (oral presentation) – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Mini oral – Short presentation by the authors with comment and interactive audience discussion led by an invited expert.
  • Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Congress.


All accepted abstracts will be published as a supplement to the official ESMO journal Annals of Oncology.

Merit Awards

A restricted number of Merit Awards to ESMO Breast Cancer 2020 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Breast Cancer 2020 Scientific Committee on a competitive basis from among the accepted abstracts. 

To apply for a Merit Awards, the following documents must be received by the ESMO Registration Services Unit on or before 4 February 2020:

  1. A letter of introduction by the applicant. Please include the following general information:
    • How relevant are the topics presented during this Congress to your current practice and research?
    • Have you attended any event on a similar topic in the last 3 years?
    • How do you believe your attendance at this Congress will help you improve your knowledge in the field and your professional development?
    • How do you consider that the findings published in your abstract make a relevant contribution to the topics presented during this Congress?
    • Have you recently been awarded an ESMO Merit Awards/ Travel Grant? If yes, for which event?
  2. A copy of the submitted abstract (the applicant must be the first author and presenter)
  3. A readable photocopy of either identity card or passport
  4. A short curriculum vitae (maximum 2 pages)

Documentation must be sent by e-mail to: ESMO will provide the recipients with a subsidised travel ticket, subsidised accommodation and Congress registration. Merit Awards recipients must submit a report detailing the benefits of participating in ESMO Breast Cancer 2020 by 4 February 2020.

Incomplete applications will not be considered.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings